|
|
||||||||





* Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461;
Department of Dermatology, Bocage Hospital, Dijon, France;
Department of Medicine, Columbia University, NY 10032; and
School of Biosciences, University of Birmingham, Edgbaston, United Kingdom
CD1d-restricted NKT cells expressing invariant TCR
-chain rearrangements (iNKT cells) have been reported to be deficient in humans with a variety of autoimmune syndromes and in certain strains of autoimmune mice. In addition, injection of mice with
-galactosylceramide, a specific glycolipid agonist of iNKT cells, activates these T cells and ameliorates autoimmunity in several different disease models. Thus, deficiency and reduced function in iNKT cells are considered to be risk factors for the development of such diseases. In this study we report that the development of systemic lupus erythematosus in (New Zealand Black (NZB) x New Zealand White (NZW))F1 mice was paradoxically associated with an expansion and activation of iNKT cells. Although young (NZB x NZW)F1 mice had normal levels of iNKT cells, these expanded with age and became phenotypically and functionally hyperactive. Activation of iNKT cells in (NZB x NZW)F1 mice in vivo or in vitro with
-galactosylceramide indicated that the immunoregulatory role of iNKT cells varied over time, revealing a marked increase in their potential to contribute to production of IFN-
with advancing age and disease progression. This evolution of iNKT cell function during the progression of autoimmunity may have important implications for the mechanism of disease in this model of systemic lupus erythematosus and for the development of therapies using iNKT cell agonists.
This article has been cited by other articles:
![]() |
M. M. Venkataswamy, A. Baena, M. F. Goldberg, G. Bricard, J. S. Im, J. Chan, F. Reddington, G. S. Besra, W. R. Jacobs Jr., and S. A. Porcelli Incorporation of NKT Cell-Activating Glycolipids Enhances Immunogenicity and Vaccine Efficacy of Mycobacterium bovis Bacillus Calmette-Guerin J. Immunol., August 1, 2009; 183(3): 1644 - 1656. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. To, A. Agrotis, G. Besra, A. Bobik, and B.-H. Toh NKT Cell Subsets Mediate Differential Proatherogenic Effects in ApoE-/- Mice Arterioscler Thromb Vasc Biol, May 1, 2009; 29(5): 671 - 677. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Wang, S. Cho, A. Ueno, L. Cheng, B.-Y. Xu, M. D. Desrosiers, Y. Shi, and Y. Yang Ligand-Dependent Induction of Noninflammatory Dendritic Cells by Anergic Invariant NKT Cells Minimizes Autoimmune Inflammation J. Immunol., August 15, 2008; 181(4): 2438 - 2445. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Tsukamoto, M. Ohtsuji, W. Shiroiwa, Q. Lin, K. Nakamura, H. Tsurui, Y. Jiang, K. Sudo, H. Nishimura, T. Shirai, et al. Aberrant Genetic Control of Invariant TCR-Bearing NKT Cell Function in New Zealand Mouse Strains: Possible Involvement in Systemic Lupus Erythematosus Pathogenesis J. Immunol., April 1, 2008; 180(7): 4530 - 4539. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Loh, Y.-C. Cai, G. Bonventi, G. Lajoie, R. MacLeod, and J. E. Wither Dissociation of the Genetic Loci Leading to B1a and NKT Cell Expansions from Autoantibody Production and Renal Disease in B6 Mice with an Introgressed New Zealand Black Chromosome 4 Interval J. Immunol., February 1, 2007; 178(3): 1608 - 1617. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |